Vol 50 No 10

Consider financial toxicity when recommending novel hormonal therapies for prostate cancer

September 27, 2022

"Ultimately, it will be the treating physician’s responsibility to identify cost-effective alternatives and available resources to help mitigate the financial toxicity incurred from novel cancer therapies," writes Badar M. Mian, MD.

Pushing past the pandemic’s impact on prostate cancer screening

September 26, 2022

"Cancer doesn’t take a holiday or vacation, and it doesn’t care about a pandemic. Our efforts to reduce deaths from prostate cancer through screening and early detection must continue," writes Michael S. Cookson, MD, MMHC.

Botox, sacral nerve stimulation highlighted as emerging OAB treatments for elderly patients

September 15, 2022

Two studies shared at the 2022 Annual Meeting of the South Central Section of the AUA highlighted onabotulinumtoxinA and sacral nerve stimulation as alternative treatment options for patients older than 70 years with overactive bladder.

Long-term data support MRI-guided TULSA for localized prostate cancer

September 05, 2022

"The biggest advantage of this technique is that because the sound waves are coming from inside and going outwards, it doesn't destroy anything beyond the prostate, at least in theory,” said Michael Koch, MD.